GAMA reveals plans for £2m R&D facility

GAMA Healthcare, a leader in the manufacture and development of infection prevention products for the healthcare sector, has outlined plans to build a new research and development facility in the Greetland area of Halifax.

The proposed development, spread across 11,765 sq ft, is projected to cost £2 million and comprises a contemporary open-office environment with advanced research laboratories and auxiliary space to produce and test product samples.

Managing director and co-founder of GAMA Healthcare, Dr Guy Braverman said: “Plans for the new R&D facility are geared towards facilitating an up-to-date environment for research and innovation breakthroughs with industry leading practices. The laboratories will be capable of conducting detailed up-to-date research in all aspects of microbiology, infection control and analytical chemistry. A pilot plant is being incorporated to allow experimental small product runs enabling our teams to conduct trials and be proactive with quality assurance and internal testing. The facility will also incorporate a mock hospital room to replicate real life scenarios.”

 

Other news

Upcoming Events

HEALTH+CARE 2018

ExCeL London
27th-28th June 2018

AfPP Residential Conference 2018

University of York
9th - 12th August

BES Healthcare Seminar

Imperial Hotel, London
5th and 6th September 2018

Infection Prevention 2018

Scottish Events Campus, Glasgow
30th September - 2nd October 2018

The 11th Healthcare Infection Society International Conference

ACC Liverpool
26th - 28th November 2018

Latest Issue

Clinical Services Journal

Clinical Services Journal

Jun 2018

Ensuring standards & peace of mind

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Aug 2017

Technology with the vision to make surgery better

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.